Arcutis Biotherapeutics reports Q3 EPS of $0.06
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million
Lucara Diamond Raises 2026 Revenue Guidance to USD 140 Million-160 Million Lucara Diamond raised
L impact | EARNINGS | Nov 14, 2026, 01:10 AM UTC
Gilead Expects HIV Revenue to Grow About 12% in 2026
Gilead expects HIV revenue to grow about 12% in fiscal 2026.
M impact | EARNINGS | Nov 14, 2026, 12:44 AM UTC
Asante Gold Withdraws 2026 Production and Cost Guidance
Asante withdrew its 2026 guidance for 275,000–300,000 equivalent ounces at consolidated AISC of $3,200–$3,600/oz after Bibiani underperformed. Nine-month production was 165,594 equ
M impact | EARNINGS | Nov 13, 2026, 11:27 PM UTC
Japan's FiEE 9M Revenue More Than Quadruples
FiEE's nine-month revenue more than quadrupled, attributed to SaaS expansion.
M impact | EARNINGS | Nov 13, 2026, 10:28 PM UTC
Equity Index futures dip on tech selling, hold weekly gains.
Equity Index futures traded lower on Friday as technology sector weakness and rising yields weighed on markets, though major indices remained on track for weekly gains. E-mini S&P
H impact | EARNINGS | Nov 13, 2026, 10:00 PM UTC
Indaptus Therapeutics Reports $5.4 Million Nine-Month Loss
Indaptus Therapeutics reported a net loss of $5.4 million for the first nine months of 2026, down from $12.7 million a year earlier. Third-quarter net loss was $1.0 million versus
M impact | EARNINGS | Nov 13, 2026, 09:34 PM UTC